Citalopram dose reductions in response to safety warning increased hospitalization

A group of Department of Veterans Affairs (VA) patients who had their citalopram doses reduced after a federal safety communication about doses exceeding 40 mg/day experienced a significant increase in hospitalizations and deaths compared with patients whose doses were not reduced, a study has found. The study's authors suggested that the Food and Drug Administration's (FDA's) 2011 safety communication appears to have generated unintended clinical consequences. Study results were published online May 10 in the American Journal of Psychiatry.
Source: The Brown University Psychopharmacology Update - Category: Psychiatry Tags: Adverse Events Source Type: research